Evidence-Based Guide • Updated June 2026

TIL Therapy: Harnessing Your Body’s
Natural Defenses Against Cancer

Tumor-Infiltrating Lymphocyte (TIL) therapy is a groundbreaking, FDA-approved cellular treatment. It takes the immune cells that have already recognized your tumor, multiplies them in a specialized lab, and returns them to fight the cancer with renewed strength. We provide clear, unbiased information to help you understand if this path is right for you.

FDA-Approved: February 16, 2024 Lifileucel (Amtagvi™) for unresectable or metastatic melanoma post-PD-1 therapy.
How It Works

The 5-Step TIL Therapy Journey

Unlike CAR-T which engineers cells, TIL therapy uses your body's own tumor-reactive immune cells — already selected by nature to recognize your specific cancer.

1

Tumor Resection

A small piece of tumor tissue is surgically removed, often from an accessible site like a skin metastasis or lymph node.

2

TIL Isolation

In a specialized GMP laboratory, tumor-infiltrating lymphocytes are carefully extracted from the tumor fragments.

3

Expansion (22-33 days)

TILs are cultured with interleukin-2 (IL-2), multiplying from thousands to 50-100+ billion cells — a targeted army.

4

Lymphodepletion

You receive a short course of chemotherapy to eliminate competing immune cells and create "space" for the new TILs.

5

TIL Infusion + IL-2

Expanded TILs are infused intravenously over ~30 minutes, followed by IL-2 support to sustain their activity.

Clinical Evidence

Real Numbers from the C-145-04 Pivotal Trial

Transparent data from the landmark study that led to FDA approval, published in the New England Journal of Medicine (2023).

36%
Objective Response Rate
In 153 patients with advanced melanoma previously treated with PD-1 and targeted therapy.
11%
Complete Response Rate
Complete disappearance of all detectable cancer — a significant achievement in advanced stages.
85%
Durable Responses
Of those who responded, 85% maintained their response for 6 months or longer, many exceeding 2 years.
44%
Cervical Cancer ORR
In Phase 2 trials for PD-1 refractory cervical cancer (investigational indication).
Patient Selection

Is TIL Therapy Right for You?

A thorough, expert review of your specific case ensures this intensive therapy is a viable option, helping you avoid unnecessary stress and expenses.

Typically a Good Candidate If

  • Diagnosed with unresectable or metastatic melanoma.
  • Disease progressed after PD-1 inhibitor therapy.
  • ECOG performance status 0-1 (fully or mostly active).
  • Adequate heart, lung, liver, and kidney function.
  • At least one resectable tumor site is available for TIL harvest.

May Not Be Suitable If

  • No resectable tumor site is available (TILs must come from your tumor).
  • ECOG performance status 3-4 (bedridden >50% of waking hours).
  • Severe cardiac or pulmonary disease.
  • Active uncontrolled infection or severe autoimmune disease.

Requires Expert Review If

  • Non-melanoma solid tumors (currently available via clinical trials).
  • Age >70 years (evaluated on a case-by-case physiologic basis).
  • History of severe immune-related adverse events from prior therapies.
  • Stable/treated brain metastases.
Transparent Pricing

TIL Therapy Cost by Region

Self-pay international patient estimates. We believe in full financial transparency to help you plan effectively.

Region Estimated Cost (USD) What's Typically Included Notes
🇨🇳 China $80,000 – $120,000 Clinical research programs TIL manufacturing, lymphodepletion, infusion, IL-2, hospital stay Multiple specialized centers in Beijing, Shanghai, Guangzhou
🇸🇬 Singapore $100,000 – $150,000 Private centers Full episode of care, English-speaking multidisciplinary teams Established TIL programs at major cancer centers
🇺🇸 USA (Amtagvi) $375,000+ Drug list price only Drug only; hospital, ICU, IL-2 add $100K-$200K+ Total episode often $500K-$700K. Highly insurance-dependent.
Important Planning Note

Costs above reflect the treatment episode. They do NOT include international airfare, accommodation for you or a companion, pre-treatment diagnostics, or post-treatment follow-up scans. Our coordination team provides a detailed, itemized estimate after reviewing your case.

Treatment Timeline

From Review to Infusion: 6-10 Weeks

TIL therapy requires more time than some other therapies due to surgical harvest and extended manufacturing. Plan for 2-3 weeks in-country.

1
Week 1

Medical Records Review & Center Matching

Share your pathology reports and treatment history. Our independent oncology coordinators conduct a peer review and match you to appropriate TIL centers within 48 hours.

2
Week 2

Travel & Surgical Tumor Resection

Travel to the destination country. A surgical procedure (often outpatient or 1-night stay) obtains the tumor tissue, which is then shipped to the GMP manufacturing lab.

3
Weeks 2-6

TIL Manufacturing & Expansion

TILs are isolated and expanded over 22-33 days. You may return home or stay near the treatment center while quality control testing is performed.

4
Week 6-7

Admission, Lymphodepletion & Infusion

Hospital admission for 3 days of lymphodepleting chemotherapy, followed by the one-time TIL infusion, and up to 12 doses of IL-2 over 5 days with close monitoring.

5
Week 8+

Follow-Up & Response Assessment

First response scan at 4-8 weeks post-infusion. You return home with a clear, coordinated follow-up plan for your local oncologist.

Honest Discussion

Side Effects: What to Expect

TIL therapy is intensive, and transparency about side effects is crucial for your peace of mind. Most effects are temporary and carefully managed by experienced medical teams.

Cytokine Response (from IL-2)

Fever, chills, fatigue, and nausea are common during IL-2 administration. These typically resolve within 24-48 hours of stopping IL-2.

Manageable

Capillary Leak Syndrome

IL-2 can cause fluid to shift from blood vessels, leading to low blood pressure or edema. This is why ICU-capable monitoring is a strict requirement.

Requires ICU Monitoring

Prolonged Cytopenias

Low white cells, red cells, and platelets for 1-3 weeks due to lymphodepletion. Infection risk is proactively managed with prophylactic medications.

Expected & Monitored
Side-by-Side

TIL vs Other Cellular Therapies

Each advanced therapy has distinct strengths. Understanding these helps you and your doctor make the most informed decision.

Dimension 🔬 TIL Therapy 🧬 CAR-T Therapy 🛡️ NK Cell Therapy
Best For Melanoma, Cervical, Solid tumors Blood cancers (ALL, DLBCL, Myeloma) Blood cancers & adjuvant solid tumors
FDA Approval Yes (Feb 2024, melanoma) Yes (Multiple products) No (Clinical trials only)
Est. Cost (China) $80K – $120K $50K – $80K $30K – $50K
Timeline 6-10 weeks 4-8 weeks 2-4 weeks
Cell Source Tumor tissue (Autologous) Blood (Autologous) Off-the-shelf (Allogeneic) OK
FAQ

Frequently Asked Questions

Honest, clear answers based on published clinical data and our coordination experience.

Is TIL Therapy Right for Your Case?

Share your medical reports for a confidential, no-obligation review by our independent oncology coordinators. We will respond within 48 hours with an honest assessment of your options.

Request Free Case Review